

US Liquid Biopsy Market is Poised to Generate Sales of US\$ 10,798 Million By 2031 | Astute Analytica

CHICAGO, UNITED STATES, September 13, 2023

/EINPresswire.com/ -- [United States liquid biopsy market](https://www.astuteanalytica.com/request-sample/united-states-liquid-biopsy-market) revenue was US\$ 3,405.8 million in 2022 and is projected to generate sales of US\$ 10,798 million by 2031, growing at a CAGR of 13.68% during the forecast period from 2023 to 2031.

For more information, contact info@astuteanalytica.com

<https://www.astuteanalytica.com/request-sample/united-states-liquid-biopsy-market>

The US liquid biopsy market has grown significantly in recent years due to technological developments, an increase in the prevalence of cancer and chronic diseases, and other factors. The market is anticipated to expand further. The number of tests carried out each year could rise by 20% as liquid biopsies gain acceptance and are fully incorporated into clinical practice.

The incorporation of AI has been one of the most important factors in this rise. Over the past five years, the use of AI in liquid biopsy analysis has increased at a remarkable pace of about 28% yearly. In contrast to the several hours needed by conventional approaches, a 2022 study by the University of California demonstrated that an AI-powered computer could interpret liquid biopsy data in just 30 minutes. Additionally, a study from 2022 that was published in the journal "Cancer Research" showed that an AI algorithm could identify particular cancer mutations from liquid biopsy data with a 95% accuracy rate. This accuracy surpasses the 85% attained by conventional data analysis techniques by a wide margin.

Government regulations and laws are shaping the global market positively. As of 2023, the FDA had approved 12 liquid biopsy procedures for various cancer types, indicating a rising level of clinical acceptance for this technology. The Precision Medicine Initiative's \$215 million funding from the US government has also helped the market. The number of tests carried out each year could rise by 20% as liquid biopsies gain acceptance and are more fully incorporated into clinical practice.



In 2023, the National Cancer Institute estimates that there will be about 2.0 million cancer diagnoses in the country. Nearly 50% of all new instances of cancer in the US are breast, lung, bronchus, prostate, and colorectal. Nearly 50% of fatalities are brought on by colorectal, pancreatic, breast, lung, and bronchus malignancies. Due to its non-invasive testing process, liquid biopsy is becoming more popular as cancer cases rise, which is helping the market expand.

Expansion of Liquid Biopsy Applications Beyond Cancer Diagnosis: Untapped Potential for Market Players

According to recent studies, liquid biopsy might also be utilized to treat infectious diseases, cardiovascular ailments, and abnormalities of the nervous system. According to several studies, liquid biopsies can find biomarkers linked to numerous non-cancerous illnesses.

For instance, a study that appeared in the "Journal of the American College of Cardiology" in 2022 showed that liquid biopsies could precisely detect particular RNA markers linked to heart failure.

Additionally, the COVID-19 pandemic has brought attention to the possibility of liquid biopsies for the diagnosis of infectious diseases. The University of Washington did research in 2020 that demonstrated the use of liquid biopsies as a complementary diagnostic method to conventional nasal swab testing for the detection of viral RNA in blood samples from COVID-19 patients.

Thus, expanding liquid biopsies' uses outside cancer detection may greatly boost the market's potential. Growing its uses might help the US liquid biopsy market, which is projected to rise to \$9.49 billion by 2030, expand even faster.

For more information, visit <https://www.astuteanalytica.com/industry-report/united-states-liquid-biopsy-market>

Multi Gene Parallel Analysis Technology Contributed More Than Half of the Revenue Share

Multi Gene Parallel Analysis has dominated the market and accounted for more than 74% of market revenue in 2022, mostly through NGS. In the upcoming years, the segment is likely to witness the highest CAGR of 13.97%, which is consistent with the current trend. The success of NGS is related to its capacity to assess numerous genes concurrently, giving a thorough picture of genetic alterations in a single test.

As a result, it is perfect for identifying resistance mutations, identifying and categorizing tumors, and monitoring therapeutic outcomes. The introduction of tailored treatment programs and targeted medications has aided in the acceptability of NGS.

Blood Samples Contributed About 69% of Market Revenue Share

In 2022, the blood sample segment generated more than 69% of the market revenue, which is the most popular choice for liquid biopsy. The blood sample market is likely to expand at a CAGR of 14.10% during the forecast period. Blood samples are preferred as they can be obtained easily and painlessly, making them a practical and patient-friendly choice.

A thorough study and precise diagnosis are made possible by the abundance of biomarkers found in blood samples, including circulating nucleic acids, circulating tumor cells (CTCs), exosomes/microvesicles, and circulating proteins. In 2022, the circulating nucleic acids are expected to dominate the market, accounting for over 36% of total market revenue, and are predicted to grow at a CAGR of 13.93%.

Competitive Landscape

The fluid biopsy market is highly fragmented and has a few significant players. The US market has grown extremely competitive as of 2023, with several well-established businesses and new startups contending for market dominance.

Leading market participant Guardant Health held a substantial market share in 2022. Precision oncology business Guardant Health Inc. (Guardant Health) commercializes cutting-edge cancer treatments. The business creates patented digital sequencing technology that may identify specific genomic changes. It provides Guardant360, a technology for early cancer identification utilized throughout cancer therapy for monitoring recurrent disease as well as residual disease.

List of Major Players

- Biocept, Inc.
- Illumina, Inc.
- Myriad Genetics, Inc.
- QIAGEN
- Thermo Fisher Scientific, Inc.
- Guardant Health
- F. Hoffmann-La Roche Ltd
- ANGLE plc
- BIODESIX
- NeoGenomics Laboratories, Inc.
- Other major players

Segmentation Outline

The United States liquid biopsy market segmentation focuses on Technology, Product, and Biomarker.

By Technology

- Multi Gene Parallel Analysis (NGS)
- Single Gene Analysis (PCR Microarrays)

By Product

- Blood Sample Based
- Others

By Biomarker

- Circulating Nucleic Acids
- CTC
- Exosomes/Microvesicles
- Circulating Proteins

Request a sample for your business @-

<https://www.astuteanalytica.com/request-sample/united-states-liquid-biopsy-market>

Request a sample for your business:

Astute Analytica is a global analytics and advisory company that has built a solid reputation in a short period, thanks to the tangible outcomes we have delivered to our clients. We pride ourselves in generating unparalleled, in-depth, and uncannily accurate estimates and projections for our very demanding clients spread across different verticals. We have a long list of satisfied and repeat clients from a wide spectrum including technology, healthcare, chemicals, semiconductors, FMCG, and many more. These happy customers come to us from all across the globe.

They are able to make well-calibrated decisions and leverage highly lucrative opportunities while surmounting the fierce challenges all because we analyze for them the complex business environment, segment-wise existing and emerging possibilities, technology formations, growth estimates, and even the strategic choices available. In short, a complete package. All this is possible because we have a highly qualified, competent, and experienced team of professionals comprising business analysts, economists, consultants, and technology experts. In our list of priorities, you-our patron-come at the top. You can be sure of the best cost-effective, value-added package from us, should you decide to engage with us.

Aamir Beg

Astute Analytica

+1 888-429-6757

[email us here](#)

Visit us on social media:

[Twitter](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/655235183>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2023 Newsmatics Inc. All Right Reserved.